--- title: 'Industry Daily Summary: What Happened on November 10, 2026' headline: Boehringer pays $358 million for options on six Sino programs description: Charles River will acquire Frontage’s Pennsylvania testing operations for about $470 million in cash. url: https://thebench.bio/news/industry/2026-11-10 topic: industry date: '2026-11-10' covers: - '2026-11-10' date_published: '2026-11-10T12:05:05Z' date_modified: '2026-11-10T12:05:05Z' tags: - Industry sources: 2 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on November 10, 2026 **Boehringer pays $358 million for options on six Sino programs** Charles River will acquire Frontage’s Pennsylvania testing operations for about $470 million in cash. ## Today in brief Boehringer Ingelheim agreed to pay $358 million upfront for options on six preclinical Sino Biopharmaceutical programs, with up to $7 billion in potential milestones. [1] Charles River agreed to acquire Frontage’s Pennsylvania testing business for about $470 million, plus up to $75 million tied to future performance. [2] ## Boehringer takes options on six Sino programs Boehringer Ingelheim agreed to pay Sino Biopharmaceutical $358 million upfront for options on six preclinical programs. [1] The programs include antibody-drug conjugates and T cell engagers, and the agreement carries up to $7 billion in potential milestone payments. [1] The companies reached the agreement on November 4. [1] ## Charles River to buy Frontage’s Pennsylvania testing operations Charles River signed definitive agreements to buy Frontage’s Pennsylvania bioanalysis and drug metabolism and pharmacokinetics operations for about $470 million in cash. [2] The transaction could include up to $75 million in additional payments, depending on the business’s future financial performance. [2] The acquisition covers two Exton sites totaling about 150,000 square feet, nearly 340 employees, and a central laboratory certified under the Clinical Laboratory Improvement Amendments. [2] The facilities test biomarkers and support bioanalysis and drug metabolism and pharmacokinetics work for large and small molecules. [2] The Pennsylvania operations generated about 40% of Frontage’s $256.7 million in 2025 revenue. [2] Charles River is part of a consortium with Frontage’s controlling shareholder, Hongkong Tigermed, and chairman Song Li that plans to take Frontage private. [2] After the planned privatization, Charles River is set to receive the Pennsylvania assets, while Tigermed and Li are to receive Frontage’s other operations. [2] Charles River CEO Birgit Girshick said the acquisition supports the company’s bioanalysis strategy and responds to demand for scientific support as biologics and complex modalities grow. [2] Charles River plans to fund the purchase with its credit facility and cash reserves, and to report the operations in its Discovery and Safety Assessment segment. [2] The parties anticipate a closing sometime in the first six months of 2027, subject to regulatory clearances, shareholder approvals, and Cayman Islands court approval. [2] ## The day in numbers - **$358 million**: Boehringer’s upfront payment for options on six Sino preclinical programs. [1] - **$7 billion**: Potential milestone payments in the Boehringer-Sino agreement. [1] - **$470 million**: Cash price for Charles River’s acquisition of Frontage’s Pennsylvania operations. [2] - **40%**: Share of Frontage’s 2025 revenue generated by its Pennsylvania operations. [2] ## Also published - [BioSpace 2027 Best Places to Work shines light on most admired employers](), BioSpace - [HP&M Recognized by Best Law Firms® as National Tier 1 – FDA Law and Regional Washington, DC Tier 1 – FDA Law (2027 Edition)](), FDA Law Blog ## Sources 1. [Boehringer in six-program tie-up with Sino: Deals Report](), BioCentury, 2026-11-10 2. [Charles River agrees $470m deal for Frontage assets](), Pharmaceutical Technology, 2026-11-10 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: